Literature DB >> 10547174

Calcium channel blockers and mortality in elderly patients with myocardial infarction.

J G Jollis1, R J Simpson, M K Chowdhury, W E Cascio, J R Crouse, M W Massing, S C Smith.   

Abstract

BACKGROUND: Although calcium channel blockers are a useful therapy in relieving angina, lowering blood pressure, and slowing conduction of atrial fibrillation, growing evidence has cast doubt on their safety in patients with coronary disease.
OBJECTIVE: To examine the association between calcium channel blocker therapy at hospital discharge and mortality in a population-based sample of elderly patients hospitalized with acute myocardial infarction.
DESIGN: Retrospective cohort study using data from medical charts and administrative files.
SETTING: All acute care hospitals in 46 states. PATIENTS: All Medicare patients with a principal diagnosis of acute myocardial infarction consecutively discharged from the hospital alive during 8-month periods between 1994 and 1995 (N = 141,041). MAIN OUTCOME MEASURE: Mortality at 30 days and 1 year.
RESULTS: Calcium channel blockers were widely prescribed at hospital discharge to elderly patients with myocardial infarction between 1994 and 1995 (n = 51,921), the most commonly prescribed being diltiazem (n = 21,175), nifedipine (n = 12,670), amlodipine (n = 11,683), and verapamil (n = 3639). After adjusting for illness severity and concomitant medication use, patients who were prescribed calcium channel blockers at hospital discharge did not have increased risk for 30-day or 1-year mortality, with the exception of the few (n = 116) treated with bepridil. Bepridil differs from other calcium channel blockers because of its tendency to prolong repolarization, and its association with proarrhythmic effects in elderly patients.
CONCLUSION: We did not identify a mortality risk in a large consecutive sample of elderly patients with myocardial infarction, which supports the need for additional prospective trials examining calcium channel blocker therapy for ischemic heart disease.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10547174     DOI: 10.1001/archinte.159.19.2341

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  5 in total

Review 1.  Treatment of coexisting diabetes and hypertension.

Authors:  N M Kaplan
Journal:  Curr Cardiol Rep       Date:  2001-11       Impact factor: 2.931

2.  Dihydropyridine calcium channel blockers and cardiovascular outcomes in elderly patients: a population-based study.

Authors:  Claudia Bucci; Muhammad M Mamdani; David N Juurlink; Jack V Tu
Journal:  Can J Cardiol       Date:  2008-08       Impact factor: 5.223

Review 3.  Has the role of calcium channel blockers in treating hypertension finally been defined?

Authors:  George S Chrysant; Steven G Chrysant
Journal:  Curr Hypertens Rep       Date:  2003-08       Impact factor: 5.369

Review 4.  Drug treatment of stable angina pectoris in the elderly: defining the place of calcium channel antagonists.

Authors:  Sanjay Kumar; Roger J C Hall
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

Review 5.  Combination therapy with renin-angiotensin system blockers: will amlodipine replace hydrochlorothiazide?

Authors:  Thor Tejada; Alessia Fornoni; Oliver Lenz; Barry J Materson
Journal:  Curr Hypertens Rep       Date:  2007-08       Impact factor: 5.369

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.